Moderna, Inc. — Director's Dealing 2020

Jul 2, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-06-30

Reporting Person: Zaks Tal Zvi (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-30	Common Stock	M	24121	$19.15	Acquired	24121	Direct
2020-06-30	Common Stock	M	15631	$19.15	Acquired	39752	Direct
2020-06-30	Common Stock	S	5400	$62.83	Disposed	34352	Direct
2020-06-30	Common Stock	S	12967	$63.56	Disposed	21385	Direct
2020-06-30	Common Stock	S	21385	$64.57	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-30	Stock Option (Right to Buy)	$19.15	M	24121	Disposed	2026-08-10	Common Stock (24121)	Direct
2020-06-30	Stock Option (Right to Buy)	$19.15	M	15631	Disposed	2026-08-10	Common Stock (15631)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.11 to $63.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.12 to $64.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.13 to $65.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: This option is fully vested and exercisable.